Literature DB >> 11793374

VEGF and bFGF are highly expressed in intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia.

Elisa Lappi-Blanco1, Ylermi Soini, Vuokko Kinnula, Paavo Pääkkö.   

Abstract

Bronchiolitis obliterans organizing pneumonia (BOOP) and usual interstitial pneumonia (UIP) are fibrous pulmonary disorders in which new fibromyxoid connective tissue is formed in distal air spaces. In BOOP this tissue is susceptible to even complete reversal, but in UIP it participates in the remodelling of the interstitium. Our previous study showed that in BOOP this newly formed intraluminal tissue is more capillarized than in UIP. This paper studies the immunohistochemical expression of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and Flk-1, and basic fibroblast growth factor (bFGF) in BOOP and UIP. It was hypothesized that there would be a difference in the expression of these angiogenic growth factors paralleling the difference in their capillarization. The results show that both VEGF and bFGF are widely expressed in BOOP and in UIP. It was shown with two different VEGF antibodies that its expression was more pronounced in the intraluminal fibromyxoid lesions in BOOP than in UIP (p<0.001 and 0.004, respectively). Similarly, bFGF also showed stronger espression in BOOP than in UIP (p<0.02) in these areas. The expression of Flt-1 and Flk-1 was in agreement with the expression of VEGF. It is concluded that the growth factors VEGF and bFGF may have an important role in the pathogenesis of BOOP and UIP; furthermore, their expression correlates with the angiogenic activity of the newly formed intraluminal fibromyxoid connective tissue in BOOP. Angiogenesis mediated by these growth factors may be one reason for the reversal of intraluminal fibromyxoid connective tissue in BOOP and for its good clinical outcome. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11793374     DOI: 10.1002/path.1038

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  12 in total

1.  Fibroblast growth factor 2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycin.

Authors:  Robert D Guzy; Ivan Stoilov; Timothy J Elton; Robert P Mecham; David M Ornitz
Journal:  Am J Respir Cell Mol Biol       Date:  2015-01       Impact factor: 6.914

Review 2.  Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.

Authors:  Talmadge E King
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

3.  Organising pneumonia in common variable immunodeficiency.

Authors:  Ziad Boujaoude; Rohan Arya; William Rafferty; Pedro Dammert
Journal:  BMJ Case Rep       Date:  2013-06-07

4.  VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats.

Authors:  Laszlo Farkas; Daniela Farkas; Kjetil Ask; Antje Möller; Jack Gauldie; Peter Margetts; Mark Inman; Martin Kolb
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

Review 5.  Hypoxia and the extracellular matrix: drivers of tumour metastasis.

Authors:  Daniele M Gilkes; Gregg L Semenza; Denis Wirtz
Journal:  Nat Rev Cancer       Date:  2014-05-15       Impact factor: 60.716

6.  Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas.

Authors:  Elvira Montero; Carmen Abreu; Paola Tonino
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-17       Impact factor: 4.553

7.  Angiogenic activity of sera from interstitial lung disease patients in relation to clinical and radiological changes.

Authors:  T M Zielonka; U Demkow; K Zycinska; M Filewska; B Bialas; J Kus; E Radzikowska; P Remiszewski; J Szopinski; A Soszka; K A Wardyn; E Skopinska-Rozewska
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

Review 8.  Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander?

Authors:  Argyris Tzouvelekis; Stavros Anevlavis; Demosthenes Bouros
Journal:  Respir Res       Date:  2006-05-25

9.  The Relationship between Remitting Seronegative Symmetrical Synovitis with Pitting Edema and Vascular Endothelial Growth Factor and Matrix Metalloproteinase 3.

Authors:  Tsuneaki Kenzaka
Journal:  Intern Med       Date:  2020-01-17       Impact factor: 1.271

10.  Human microvasculature-on-a chip: anti-neovasculogenic effect of nintedanib in vitro.

Authors:  Soheila Zeinali; Colette A Bichsel; Nina Hobi; Manuela Funke; Thomas M Marti; Ralph A Schmid; Olivier T Guenat; Thomas Geiser
Journal:  Angiogenesis       Date:  2018-07-02       Impact factor: 9.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.